Anavasi Diagnostics, an NIH/RADx funded medical technology company developing novel molecular diagnostic testing for the point-of-care (POC) market, announced the Food and Drug Administration has issued an Emergency Use Authorization (EUA) for The AscencioDx COVID-19 Test and The AscencioDx Molecular Detector.
The AscencioDx COVID-19 Test provides results for the detection of SARS-CoV-2 RNA in as little as 20 minutes. The affordability and portability of the AscencioDx system enables quality point-of-care molecular testing in a wider range of healthcare environments, including facilities such as urgent care centers, mobile testing sites, assisted nursing care centers, and more.
The test uses proprietary assay chemistry to target multiple locations on the viral genome, reducing the likelihood of missing a new strain. In addition, the AscencioDx proprietary platform will enable rapid product development of new viral and bacterial targets, including influenza, RSV, sexual health-related strains, and more.
The AscencioDx Molecular Detector’s proprietary compact design uses RT-LAMP (reverse transcription loop-mediated isothermal amplification) technology similar to more expensive and complex PCR testing, but unlike PCR testing, doesn’t require sending a sample to a different location nor waiting days for results.
The AscencioDx COVID-19 Test and The AscencioDx Molecular Detector create less biowaste because the detector is reusable for at least 3,000 test cycles. Unlike most single-use molecular tests, it doesn’t require batteries or electronic components to be thrown away after a single use. The AscencioDx system has minimal packaging and fewer disposable components than other molecular POC tests.
